What is Phylos Bioscience?
Phylos Bioscience operates as the premier authority in cannabis genomics, bridging the gap between traditional cultivation and advanced molecular science. The company utilizes a comprehensive suite of genetic testing solutions to optimize hemp and drug varieties for diverse agricultural environments. By integrating computational biology with large-scale breeding partnerships, Phylos provides the essential data infrastructure required for modern agricultural businesses to achieve consistent, high-performance yields. Their market position is defined by a unique ability to translate complex genetic data into actionable insights for global cultivation partners, effectively setting the standard for quality and consistency in the sector.
How much funding has Phylos Bioscience raised?
Phylos Bioscience has raised a total of $16M across 3 funding rounds:
Private Equity
$1.4M
Unspecified
$7.6M
Debt
$7M
Private Equity (2015): $1.4M, investors not publicly disclosed
Unspecified (2022): $7.6M led by Merida Capital Holdings, Entourage Effect Capital, and Accomplice
Debt (2024): $7M supported by OrganiGram
Key Investors in Phylos Bioscience
OrganiGram
Organigram is a leading Canadian producer of high-quality, indoor-grown cannabis, focused on international business partnerships and the development of a diverse portfolio of adult-use recreational brands.
Merida Capital Holdings
A private equity firm targeting fundamental growth in the cannabis ecosystem, with a focus on infrastructure, cultivation technology, and data-driven agricultural solutions.
Entourage Effect Capital
A specialized investment firm providing growth capital to companies across the cannabis value chain, emphasizing operational excellence and market-leading innovation.
What's next for Phylos Bioscience?
With the recent infusion of capital, Phylos Bioscience is well-positioned to accelerate its research and development pipeline, focusing on the refinement of genetic traits that enhance resilience and productivity in varied climates. The strategic focus will likely shift toward deepening its integration with global agricultural supply chains and expanding its suite of genetic testing services to meet the increasing demand for standardized, high-quality cannabis and hemp products. As the regulatory landscape continues to evolve, the company's emphasis on data-driven breeding and molecular precision will be critical in maintaining its competitive advantage and securing its role as an indispensable partner for large-scale cultivation enterprises worldwide.
See full Phylos Bioscience company page
